AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05075460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tucidinostat, Azacitidine combined with CHOP
Description: Azacitidine: 200 mg D1200 mg D2100 mg D3 subcutaneous injection Tucidinostat: 20mg / time, D1, 4, 8, 11; Take medicine with 200ml warm boiled water 30 minutes after breakfast.~CHOP chemotherapy:~* Cyclophosphamide (CTX) 750mg / m2 intravenous infusion, day 1;~* Epirubicin (EPI) 70mg / m2 intravenous infusion, day 1;~* Vinoresin (VDS) 4mg intravenous infusion, day 1;~* Prednisone 100mg orally, day 1-5. Every 21 days is a course of treatment
Study NCT05075460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucidinostat, Azacitidine combined with CHOP
Description: Azacitidine: 200 mg D1200 mg D2100 mg D3 subcutaneous injection Tucidinostat: 20mg / time, D1, 4, 8, 11; Take medicine with 200ml warm boiled water 30 minutes after breakfast.~CHOP chemotherapy:~* Cyclophosphamide (CTX) 750mg / m2 intravenous infusion, day 1;~* Epirubicin (EPI) 70mg / m2 intravenous infusion, day 1;~* Vinoresin (VDS) 4mg intravenous infusion, day 1;~* Prednisone 100mg orally, day 1-5. Every 21 days is a course of treatment
Study NCT05282108 — intervention group
Intervention type: DRUG
Intervention: Carcemia
Description: Generic Imatinib
Study NCT05749029 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Four Week Self-Compassion Course
Description: This is a four-week self-compassion course supplied by Balanced Minds. The owner of Balanced Minds is a Consultant to this study, who will be providing access to participants.~The self-help, self-compassion course is based on Compassionate Mind Training. This provides participants with opportunities to develop skills and attributes of compassion through a weekly 30-minute video on a specified topic, a 10-minute compassionate exercise that participants are encouraged to engage in daily for the week and a brief summary of the compassionate topic. The topics of the course are:~1. The Foundations of Self-Compassion~2. Developing your Compassionate Self~3. Deepening the Compassionate Relationship with Yourself~4. Self-compassion in Everyday Life.
Study NCT05282108 — intervention group
Intervention type: DRUG
Intervention: Glivec
Description: Imatinib
Study NCT06535165 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Red Beetroot Juice
Description: 200ml/d for 14 days
Study NCT06535165 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 200ml/d for 14 days
Study NCT06625437 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy
Description: Acceptance and commitment therapy is a psychotherapy focused at increasing psychological flexibility and an individual\&#39;s engagement in valued activities rather than focusing solely or primarily on reducing psychiatric symptoms
Study NCT05493657 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin single antiplatelet therapy
Description: Patients receive the aspirin (100 mg/day) single antiplatelet therapy after 4 weeks of dual antiplatelet therapy of aspirin (100 mg/day) and clopidogrel (75 mg/day) after TAVR.
Study NCT05331651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrronium in Combination With Tropisetron
Description: Glycopyrronium (0.2mg) in Combination With Tropisetron (4mg) intravenously given at the ending of the surgery.
Study NCT05331651 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline in Combination With Tropisetron
Description: Normal Saline in Combination With Tropisetron (4mg) intravenously given at the ending of the surgery.
Study NCT05493657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel single antiplatelet therapy
Description: Patients receive the clopidogrel (75 mg/day) single antiplatelet therapy after 4 weeks of dual antiplatelet therapy of aspirin (100 mg/day) and clopidogrel (75 mg/day) after TAVR.
Study NCT05967169 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal Septal Strap implantation
Description: Correction of NSD with Nasal Septal Strap implant
Study NCT06700980 — intervention group
Intervention type: OTHER
Intervention: Focus Group
Description: Dutch-speaking patients, Dutch- and/or French-speaking general practitioners and Dutch- and/or French-speaking representatives from pertinent organizational and policy sectors will be questioned in heterogeneous focus groups, identifying barriers and facilitators to the use of technological translation tools in Brussels out-of-hours primary care services for Dutch-speaking patients and French-speaking general practitioners.
Study NCT06748638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulose
Description: At 20:00 the night before the examination, pour 2 boxes of lactilose into a cup, add 1000ml of water and drink it; 4 to 6 hours before the examination, dissolve the third box of lactulose into 1000ml water, and drink it; Until pale yellow or clear dung water is drawn.
Study NCT06748638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulose+ linaclotide
Description: 1 capsule of linalotide (290ug) taken orally half an hour before meal at 12:00 noon on the previous day， and two doses were taken after 20:00 according to the above Lactulose-taking method.
Study NCT06748638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: polyethylene glycol (PEG)
Description: a bag of PEG was dissolved into 1L at 20:00 1d before the examination, and was drunk at a constant rate within 2h; 4 to 6 hours before the inspection, dissolve the second bag of PEG into 2L water and drink it.
Study NCT06750510 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digitally Delivered Parent Training
Description: The intervention is a universal, digitally delivered parenting program, including 5 themes with recommended length of 1 week each. The total length of the intervention is 8 weeks. The program focuses on positive parenting, encouraging to develop parenting skills that strengthen their relationships and communication with their children.
Study NCT06751134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chimeric Natural Killer Receptor Universal T-cells (CNK-UT)
Description: OUTLINE: This is a dose-escalation study of CNK-UT cells followed by a dose-expansion study.~1. Dose Escalation (Single Ascending Dose Study, SAD): During SAD study stage, the participants will be intravenous infused with CNK-UT cells (3\~34×10\^7 CNK+ cells/kg)with a3 +3 design to determine the maximum tolerated dose. During single ascending dose (SAD) study stage, the participants will receive a single dose of CNK-UT cells before the DLT observation period (21 days). If the participants do not experience DLT, they will be able to enter a multiple ascending dose (MAD) study stage.~2. Dose Expansion (multiple ascending dose study, MAD): During MAD study stage, the participants will receive multiple doses of CNK-UT cells. The dosage and frequency of drug administration in the dose expansion stage can be adjusted and determined according to the SAD study.
Study NCT06750926 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: video image through laryngeal mask specific channel
Description: patients placed SaCoVLM will be checked the proper position of placement by native camera through specific video channel and fiberoptic endoscopy through ventilation channel perspectively
Study NCT06749769 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: simulation-based education
Description: Patients will learn how to care for their stomata on a stoma simulator
Study NCT06750458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin placebo
Description: Twenty-five non-diabetic glioma patients on levetiracetam, and not on SGLT2 inhibitors will receive Dapagliflozin 10 mg once daily for 14 days pre-operative
Study NCT06750458 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twenty-five non-diabetic glioma patients on levetiracetam, and not on SGLT2 inhibitors will receive placebo tablets once daily for 14 days pre-operative.
Study NCT06750458 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DexamethasoneGroup III (n=25) (Dexamethasone group)
Description: Twenty-five non-diabetic glioma patients on levetiracetam, and not on SGLT2 inhibitors will receive Dexamethasone 8 mg tablets once daily for 14 days pre-operative.
Study NCT06748352 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FASTER-assisted ESD
Description: The patients who are randomly assigned to the FASTER-assisted ESD group will undergo the ESD procedure with the assistance of the FASTER system.
Study NCT06748352 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional ESD
Description: The patients who are randomly assigned to the conventional ESD group will undergo the ESD following the clinically established pattern.
Study NCT06749470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jieyu Chufan Capsules
Description: 4 capsules, tid; 8 weeks
Study NCT06749470 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Jieyu Chufan Capsules simulant
Description: 4 capsules, tid; 8 weeks
Study NCT06750809 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PermeaDerm Biosynthetic Wound Matrix
Description: Study participants randomized (1:1) to this arm will receive PermeaDerm Biosynthetic Wound Matrix prior to skin graft.
Study NCT06750809 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Frozen Human Cadaveric Allograft (FHCA)
Description: Study participant randomized (1:1) to this arm will receive Frozen Human Cadaveric Allograft (FHCA) prior to skin graft.
Study NCT06750198 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hip focused
Description: Group A will be treated with hip focused exercises and standard rehabilitation protocol.~Hip focused exercises will be comprised of following exercises in phase 1 will be Side lying hip abduction, Hip abduction in standing, Hip extension from prone, Single leg bridge, Side lying clam with resistance while exercises in phase 2 will be same with more repetitions in addition to Side lunges, Forward lunges
Study NCT06750198 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard rehabilitation
Description: Group B will be only be treated with standard rehabilitation protocol. When participant reach full ROM of knee, perform four sets of 20 repetitions of straight leg raising with full extension, and maintain one minute single leg balance on a solid surface with the affected side, subject can transfer to phase 2
Study NCT06750198 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard rehabilitation
Description: Group B will be only be treated with standard rehabilitation protocol. When participant reach full ROM of knee, perform four sets of 20 repetitions of straight leg raising with full extension, and maintain one minute single leg balance on a solid surface with the affected side, subject can transfer to phase 2
Study NCT06000683 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient education
Description: Patients will be sent information (in preferred language) on lung cancer risk, lung cancer screening (LCS) benefits, harms, false positive rates, recommendations of follow-up for positive results, and exam insurance coverage.
Study NCT06000683 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Referral to financial navigation resources
Description: Patients who self-report needing help with health-related social risks at baseline will be sent a brochure (in preferred language) from patient advocate foundation (PAF), a national non-profit financial navigation organization, where patients can self-refer.
Study NCT06000683 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Reminders
Description: Within 2 weeks prior to primary care appointment, patients will receive a text message or a phone call (if not having a phone that receives text messaging) encouraging patients to discuss the LCS with their provider.
Study NCT06000683 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider Reminers
Description: Within 2 weeks prior to primary care appointment, providers will be notified of their patient's eligibility for LCS.
Study NCT06749873 — intervention group
Intervention type: OTHER
Intervention: Background of different SP information
Description: Sp was asked with the following baseline information: 1. 50 years of age and gender; 2. positive urea breath test; 3. asymptomatic; 4. family history of gastric cancer; 5. gastroscopy: atrophic gastritis; 6. untreated; and 7. no history of drug allergies.
Study NCT06749119 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Free gingival graft operation
Description: Free gingival graft was harvested from palatal region and stabilized on the maxillary anterior recipient bed with sutures .
Study NCT06748456 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Podcast
Description: A pre-recorded podcast with a urologist and a GP discussing the theme to promote preparatory reflections among the GPs before the cluster meeting
Study NCT05373277 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one tablet of placebo twice daily for two days
Study NCT05373277 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Intervention Description: 90 mg tablet twice daily for two days
Study NCT06276699 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: 1.Isometric exercise 2.combined conservative treatment
Description: Exercise programs will be taught to patients with details by an experienced physiotherapist at the beginning of the study. Cervical Traction Patient will sit upright posture on a chair. Mechanical traction will be applied. It includes placement of a halo device around the neck, then the harness will be attached to the machine that applies traction force through-out the treatment, the device is controlled by the control panel. Intermittent mechanical traction will be applied for 10 minutes in which pull for 10 seconds and 5 seconds rest will be applied. Neural mobilization will be carried out using Butler's approach. The subject will be positioned in supine, and the median nerve will be mobilized using a slider.
Study NCT06276699 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 1.Isometric exercise 2.combined conservative treatment
Description: Exercise programs will be taught to patients with details by an experienced physiotherapist at the beginning of the study. Cervical Traction Patient will sit upright posture on a chair. Mechanical traction will be applied. It includes placement of a halo device around the neck, then the harness will be attached to the machine that applies traction force through-out the treatment, the device is controlled by the control panel. Intermittent mechanical traction will be applied for 10 minutes in which pull for 10 seconds and 5 seconds rest will be applied. Neural mobilization will be carried out using Butler's approach. The subject will be positioned in supine, and the median nerve will be mobilized using a slider.
Study NCT06152705 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive Transcranial Magnetic Stimulation
Description: Repetitive transcranial magnetic stimulation (rTMS) is a Health Canada approved treatment for major depression. Typical treatments involve 30 to 45 minutes daily sessions delivered over 4 to 6 weeks. Recent technical advances allowed the development of theta burst stimulation (TBS), a novel rTMS paradigm that reduces daily sessions to 3 to 4 minutes while maintaining the same clinical efficacy. This study will specifically be administering intermittent TBS (iTBS), which is a novel refinement of conventional rTMS and consists of bursts of 3 stimulations at 50 Hz at theta frequency (5 Hz).
Study NCT06152705 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive Transcranial Magnetic Stimulation
Description: Repetitive transcranial magnetic stimulation (rTMS) is a Health Canada approved treatment for major depression. Typical treatments involve 30 to 45 minutes daily sessions delivered over 4 to 6 weeks. Recent technical advances allowed the development of theta burst stimulation (TBS), a novel rTMS paradigm that reduces daily sessions to 3 to 4 minutes while maintaining the same clinical efficacy. This study will specifically be administering intermittent TBS (iTBS), which is a novel refinement of conventional rTMS and consists of bursts of 3 stimulations at 50 Hz at theta frequency (5 Hz).
Study NCT05424250 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: occasional aversive imagination
Description: During six of the 27 exposure trials, participants in the experimental group are asked to imagine their most feared outcome towards spiders as vividly as possible while completing the specific trial.
Study NCT05424250 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure
Description: • All participants complete an exposure training session (approx. 75 min) with seven exposure steps, which are repeated between one and five times (e.g. Step 4: directing the spider with a pen by touching its legs at least five times per repetition; this step must be repeated five times before continuing to the next step). One repetition per step is considered one trial, therefore each participant aims to complete 27 exposure trials.
Study NCT05424250 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure
Description: • All participants complete an exposure training session (approx. 75 min) with seven exposure steps, which are repeated between one and five times (e.g. Step 4: directing the spider with a pen by touching its legs at least five times per repetition; this step must be repeated five times before continuing to the next step). One repetition per step is considered one trial, therefore each participant aims to complete 27 exposure trials.
Study NCT05567016 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active case detection using molecular testing (ACDm)
Description: In the ACDm arm, children will receive ACD using RDT and qPCR 3x yearly with treatment using artemether-lumefantrine (AL) if RDT or qPCR positive. With fevers, participants will receive standard PCD using RDT.
Study NCT05567016 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive case detection using molecular testing (PCDm)
Description: With fevers, participants will receive PCDm, in which qPCR will be done in RDT negatives with treatment using AL if positive.
Study NCT05567016 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control (standard of care)
Description: With fevers, participants will receive standard PCD using RDT with treatment using AL if positive.
Study NCT05373277 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rosuvastatin
Description: 10 mg tablet, single dose
Study NCT05373277 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: 10 mg tablet, single dose
Study NCT06030050 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Animal-assisted intervention
Description: The AAI is designed to promote patient comfort, uplift mood, and provide an opportunity for socialization. The nature of the dog interaction involves several different components, including but not limited to: petting the dog, talking to the dog, watching the dog do tricks, conversing with the dog handler, and being prompted to discuss any fond memories/stories of their own personal experiences with human-animal interactions. Therapy dogs are trained and certified animals who are leashed at all times and under direct care of their dog handler, NOT companion animals, personal pets, nor emotional support animals.
Study NCT06748456 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cluster meeting
Description: A two-hour meeting facilitated by either the GPs cluster coordinator, another GP from the cluster or a facilitator outside the cluster chosen by the cluster itself with specific slides about PSA in general, guidelines, expert videos, data from the clinics, cases, and group discussions
Study NCT06748456 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hand-out material 1
Description: Hand-outs of the main take-home messages to facilitate further discussion in their respective GP offices
Study NCT06748456 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hand-out material 2
Description: Hand-outs to be used by GP and patients to facilitate communication about the relevance of taking a PSA-test
Study NCT06750380 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tailored mat exercise program
Description: The Group A will receive TENS plus moist hot pack and follow the Tailored mat exercise program for 10 weeks, two times per week, in 45-min sessions under supervision of trained physical therapist. The choice of exercises will be made based on the suggested exercises of Wood for the treatment of back pain, while the easiest versions of each exercise would be selected in order for the program to be adapted to older adults. Patient's outcomes will be measured at baseline and after 10 weeks.
Study NCT06750380 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: McKenzie exercises
Description: The Group B will receive McKenzie exercises plus moist hot pack and TENS in the region of lumbar spine for 10 minutes and Mckenzie exercises of seven to ten repetitions for 45 min/session two times per week for ten weeks. Patient's outcomes will be measured at baseline and after 10 weeks.
Study NCT06751264 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peritoneal combined with intrauterine water isolation
Description: On the basis of the conventional peritoneal water isolation group, the improved technology group added additional intrauterine water isolation, and continued to inject ice saline to separate the endometrium on both sides.
Study NCT06751264 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peritoneal water isolation
Description: Transabdominal injection of saline into the abdominal cavity to achieve complete separation of the uterus from the surrounding organs and structures
Study NCT03645460 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Direct intravenous injection of ivlv-ADA lentiviral vector
Description: Injection of ivlv-ADA lentiviral vector at \~1x10\^9 per kg body weight